Contents

Introduction to Safety Assessment in Drug and Medical Device Development 1
Global Pharmaceutical and Medical Device Markets 2
Legislative Considerations 6
Regulations: Human Pharmaceuticals 8
Special Cases: Biologics and Combination Products 10
Strategies for Development 10
Drugs 10
What You Need to Know to Start 12
Devices 13
References 15

Drugs: The General Case 17
IND/FIM Enabling 19
To Support Continued Clinical Development 19
To Support Marketing Approval 20
Subset: Special or Hazard Studies 20
ICH Requirements: The Global General Case 21
The First Rule 21
References 21

IND-Enabling Toxicology Programs 23
Toxicity Testing: Traditional Pharmaceuticals 26
Common Mistakes 27
Toxicity Testing of Pharmaceuticals: The General Approach 29
Developmental and Reproductive Toxicity Studies 30
Genetic Toxicity Assessment 31
Safety Pharmacology Studies 33
Toxicity Testing: Biotechnology Products 34

Toxicology Testing: Special Cases 37
Oral Contraceptives 37
Life-Threatening Diseases (Compassionate Use) 37
Antibiotics and Anti-Infectives 38
Special Cases 39
Direct to FIM Trials: Imaging Agents 39
Gene Therapy 40
Cellular (Stem Cell) Therapy 41
Excipients 41
Pediatric Claims and Juvenile Animal Studies 42
Exploratory INDs 43
References 44

Nonclinical Safety Evaluation Studies Conducted to Support Continued Clinical Development 45
Repeat Dose Toxicity 45
Developmental and Reproductive Toxicology (DART) 45
Impurities, Degradants, and Residual Solvents 47
Impurities 47
Residual Solvents 52
Extractables and Leachables 55
Residual Metals and Metal Catalysts 57
Safety Assessment of Metabolites (Metabolites in Safety Testing – MIST) 59
Local Tissue Tolerance 62
Nonclinical Abuse Liability 62
Drug Registration in Japan 62
Drugs in China; Pharmacology and Toxicology Study Information 63
References 63

Supporting Marketing Applications 65
Non-Traditional (Other than NDA/505b (1)) Approval Routes and Requirements 65
Carcinogenicity 67
Pre- and Post-natal Development 67
Pediatric Population Studies 67
Special Cases 67
References 68

Special Therapeutic Category and Route of Administration Cases 69
Specific Therapeutic Classes 69
Oncology Drugs 69
Activity Profile and Mechanism of Action 71
Mechanism(s) of Resistance 72
Special Considerations for Biopharmaceutical Studies 74

Nonclinical Data Evaluation to Support Clinical Trial Design 75
Start Dose for First Administration in Human 75
Dose Escalation and the Highest Dose in a Clinical Trial..... 75
Duration and Schedule of Toxicology Studies to Support Initial Clinical Trials..... 75
Duration of Toxicology Studies to Support Continued Development..... 76
Combinations of Pharmaceuticals 76
Studies in Pediatric Populations 76
Special Considerations for Biologics 77
Conjugated Agents 77
Liposomal Formulated Products 77
Evaluation of Drug Metabolites 79
Evaluation of Impurities 79
Other Life-Threatening Chronic Diseases 79
Imaging Agents 79
Antibiotics 81
Vaccines..... 81
Routes and Regimens Other than Oral and Daily 82
Combination Products 82
Historical Background 83
References 88

Device Safety Evaluation 91
Introduction 91
Regulatory Definition of Medical Devices..... 91
International Standards Organization..... 92
Topical Devices 97
Blood Path Direct 100
Japan..... 101
Other Regulatory Guidances 102
Biological Tests 102
References 108
Appendices 111

About the Author 113

Appendix A Notable Regulatory Internet Addresses 115

Index..... 123